Panacea Biotec Ltd's Q3FY25 Quarter Results
- 15 Feb 2025
Result Summary
- Panacea Biotec Ltd reported a 9.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 7.0%.
- Its expenses for the quarter were up by 10.3% QoQ and 3.0% YoY.
- The net profit decreased 5.7% QoQ and decreased 301.8% YoY.
- The earnings per share (EPS) of Panacea Biotec Ltd stood at 0.7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 167.11 | 152.00 | 156.18 | 9.9% | 7.0% |
Total Expenses | 165.50 | 150.01 | 160.61 | 10.3% | 3.0% |
Profit Before Tax | 4.38 | 4.76 | -1.65 | -8.0% | -365.5% |
Tax | -0.06 | 0.05 | 0.55 | -220.0% | -110.9% |
Profit After Tax | 4.44 | 4.71 | -2.20 | -5.7% | -301.8% |
Earnings Per Share | 0.70 | 0.80 | -0.40 | -12.5% | -275.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Panacea Biotec Ltd is a well-established pharmaceutical and biotechnology company. It specializes in researching, developing, and manufacturing products in the healthcare sector, primarily focusing on vaccines, insulin, and other pharmaceutical formulations. As of the latest available data, Panacea Biotec operates within the highly competitive pharmaceutical industry, characterized by its rapid innovation and stringent regulatory environments. The company is known for its contributions to public health through the development of vaccines for serious diseases. Recent developments in the company may include strategic partnerships, new product launches, or advancements in its research and development pipeline, although specific details are not available in the provided data.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Panacea Biotec Ltd reported a total income of ₹167.11 crores. This represents a 9.9% increase from the previous quarter (Q2FY25), where total income was ₹152.00 crores. Compared to the same quarter in the previous year (Q3FY24), the total income grew by 7.0% from ₹156.18 crores. This upward trend in income indicates a positive revenue trajectory over the periods analyzed, reflecting the company's ability to generate increased sales or other income streams. The data highlights Panacea Biotec's continued growth in revenue, which could be attributed to increasing demand for its products or successful market expansion strategies.
Profitability
The profitability of Panacea Biotec Ltd in Q3FY25 shows a mixed performance. The profit before tax (PBT) for this quarter was ₹4.38 crores, reflecting an 8.0% decrease from ₹4.76 crores in Q2FY25. However, compared to Q3FY24, where the company posted a loss of ₹1.65 crores, there is a significant improvement. The profit after tax (PAT) for Q3FY25 stood at ₹4.44 crores, slightly lower than the ₹4.71 crores reported in Q2FY25, marking a 5.7% decline. Nevertheless, this is a substantial turnaround from a loss of ₹2.20 crores in the same quarter of the previous year. The earnings per share (EPS) in Q3FY25 was ₹0.70, down from ₹0.80 in the prior quarter, but up from a negative EPS of -₹0.40 in Q3FY24.
Operating Metrics
Examining the operating metrics, the total expenses for Panacea Biotec Ltd in Q3FY25 amounted to ₹165.50 crores, increasing by 10.3% from ₹150.01 crores in Q2FY25. This quarterly rise in expenses is consistent with the 3.0% year-over-year increase from ₹160.61 crores in Q3FY24. The tax expense for Q3FY25 was a negative ₹0.06 crores, which is unusual compared to the positive tax of ₹0.05 crores in Q2FY25 and ₹0.55 crores in Q3FY24. The changes in tax expenses, along with the fluctuations in profits, highlight the variability in the company's operating environment and its financial strategies. The financial data indicates Panacea Biotec's efforts to manage costs while navigating the industry’s challenges and opportunities.
